Results
At Visus Oogkliniek, we continuously measure, analyse, and publish our clinical outcomes. By systematically tracking visual results, refractive accuracy, safety indicators, and patient satisfaction, we ensure full transparency and maintain the highest quality standards in refractive and lens surgery.
This page presents two types of outcomes:
1. National Benchmark – NGRC Quality Registry
The NGRC (Dutch National Quality Registry for Refractive Surgery) provides a national benchmark for refractive surgery outcomes. The dataset shown here covers 1 January 2016 – 31 December 2016, with 5,380 eyes analysed:
- 2,294 eyes analysed at Visus Oogkliniek
- 3,086 eyes representing the national benchmark
NGRC evaluates four internationally recognised quality indicators:
- Predictability – % of eyes within ±1.0 D of target refraction
- Safety – % losing ≥2 lines of CDVA
- UCVA ≥ 0.8 – functional uncorrected distance visual acuity
- Retreatment rate
These metrics allow a transparent, objective comparison between Visus Oogkliniek and other refractive centres in the Netherlands.
2. Visus Clinical Outcomes – Refractive Surgery (TransPRK, SMILE, FemtoLASIK)
This section presents outcomes from patients treated at Visus Oogkliniek, based on our internal clinical data collected between 2016 and 2024. For each procedure we evaluate:
- Uncorrected Distance Visual Acuity (UDVA) at several postoperative time points
- Refractive Predictability (±0.50 D, ±1.00 D)
- Safety Metrics (gain or loss of CDVA lines)
- Visual stability
The following procedures are included:
- TransPRK – Flapless surface ablation
- SMILE – Minimally invasive keyhole extraction
- FemtoLASIK – Femtosecond-assisted LASIK with corneal flap
These results reflect the real-world performance of refractive surgery within our clinic.
Definitions
To ensure clarity for all readers, we provide the following definitions:
- NGRC
- Dutch National Quality Registry for Refractive Surgery
- UCVA / UDVA
- Uncorrected Distance Visual Acuity (vision without glasses)
- CDVA
- Corrected Distance Visual Acuity (best vision with correction)
- ±1.0 D
- Deviation from intended refractive outcome
- Retreatment
- Additional correction procedure when needed
- ICL
- Implantable Collamer Lens (phakic intraocular lens)
- IOL
- Intraocular Lens (used in cataract surgery)
- Spectacle Independence
- Ability to perform daily activities without glasses
- D (Dioptrie)
- Unit of measurement for refractive error
Refractive Surgery Outcomes (TransPRK, SMILE, FemtoLASIK)
Visus Oogkliniek – Clinical Results Based on 40,826 Eyes Analysed (2016–2025)
This section presents the combined refractive surgery outcomes from Visus Oogkliniek between 2016 and 2025, covering a total of 40,826 analysed eyes across three primary procedures:
- SMILE: 23,851 eyes
- FemtoLASIK: 11,984 eyes
- TransPRK: 4,991 eyes
These results reflect real-world clinical performance in our patient population and provide a transparent comparison of visual acuity outcomes, refractive predictability, and safety across the three major corneal laser techniques we offer.
For each procedure we evaluate:
- Uncorrected Distance Visual Acuity (UDVA) at 1, 6 and 12 months
- Refractive Predictability, defined as the percentage of eyes within ±0.50 D and ±1.00 D of intended correction
- Safety Indicators, including line changes in corrected distance visual acuity (CDVA)
These metrics follow internationally recognised reporting standards for refractive surgery and provide clear insight into the accuracy, stability, and safety of each treatment type.
The tables below summarise the combined outcomes for all eyes treated with TransPRK, SMILE, and FemtoLASIK at Visus Oogkliniek during the selected timeframe.
Table 1a — UDVA ≥ 20/20 Over Time
Percentage of eyes achieving UDVA ≥ 20/20 at 1, 6, and 12 months, based on outcomes from 23,851 SMILE, 11,984 FemtoLASIK, and 4,991 TransPRK eyes analysed at Visus Oogkliniek.
| Time | TransPRK | SMILE | Femto-LASIK |
|---|---|---|---|
| 1 month | 77.5% | 91.5% | 91.5% |
| 6 months | 94.5% | 96.5% | 96.5% |
| 12 months | 96% | 97.5% | 97.5% |
Table 1b — UDVA ≥ 20/25 (0.8) Over Time
Percentage of eyes achieving UDVA ≥ 20/25 (0.8) at 1, 6, and 12 months, based on outcomes from 23,851 SMILE, 11,984 FemtoLASIK, and 4,991 TransPRK eyes analysed at Visus Oogkliniek.
| Time | TransPRK | SMILE | Femto-LASIK |
|---|---|---|---|
| 1 month | 92.5% | 95.5% | 95.5% |
| 6 months | 96.5% | 97.5% | 97.5% |
| 12 months | 97.5% | 98% | 98% |
Table 2 — Refractive Predictability (Spherical Equivalent)
Percentage of eyes within ±0.50 D and ±1.00 D of intended correction at 6–12 months for all Visus-treated TransPRK, SMILE, and FemtoLASIK eyes (2016–2025).
| Metric (6–12 months) | TransPRK | SMILE | Femto-LASIK |
|---|---|---|---|
| Within ±0.50 D of target | 91% | 95.5% | 95.5% |
| Within ±1.00 D of target | 98% | 98.5% | 98.5% |
| Mean residual SE (D) | 0.00 to −0.25 | 0.00 to −0.25 | 0.00 to −0.25 |
Table 3 — Safety (CDVA Line Changes)
Distribution of CDVA gains and losses at 12 months, summarising safety outcomes for 40,826 refractive surgery eyes analysed at Visus Oogkliniek.
| CDVA Outcome at 12 Months | TransPRK | SMILE | Femto-LASIK |
|---|---|---|---|
| Safety Index (CDVA postop / CDVA preop) | 1.1 | 1.1 | 1.05 |
| Eyes with ≥1 line CDVA gain | 22.5% | 22.5% | 17.5% |
| Eyes with 1 line CDVA loss | 3.5% | 3.5% | 3.5% |
| Eyes with ≥2 lines CDVA loss | <1% | <1% | <1.5% |
3. NGRC 2016 – Detailed Benchmark Data
Comparing Visus Oogkliniek with the national average | Data: 1/1/2016 – 31/12/2016 (N = 5,380)
Predictability – Percentage with refractive deviation PostOp ≤ 1D
Before treatment, we discuss a target (goal) with the patient for the strength that should be achieved. Usually this is 0. This table shows the percentage of eyes that have a deviation of less than 1 diopter after treatment.
| Source | Percentage | Number of eyes |
|---|---|---|
| Visus Oogkliniek | 99.6% | 2.294 ogen |
| Nationaal | 97.4% | 3.086 ogen |
Safety – Percentage with reduced vision (≥ 2 lines)
This table shows what percentage of eyes has more than 2 lines of vision loss during an eye examination after treatment. During the preliminary examination, the visual acuity with your glasses is determined. After treatment, we measure the visual acuity again with the remaining eye measurement.
| Source | Percentage | Number of eyes |
|---|---|---|
| Visus Oogkliniek | 0.04% | 2.294 ogen |
| Nationaal | 0.46% | 3.086 ogen |
Percentage UCVA distance PostOp ≥ 0.8
During the preliminary examination, your visual acuity is determined. This is usually 1.0. After treatment, we aim for the visual acuity without correction to be as high as the visual acuity with correction before treatment.
| Source | Percentage | Number of eyes |
|---|---|---|
| Visus Oogkliniek | 95.3% | 2.294 ogen |
| Nationaal | 91.2% | 3.086 ogen |
Retreatment
This table shows at what percentage of treatments a treatment was performed again. Situations that can lead to retreatment are, for example, over- or undercorrection after the first treatment.
| Source | Percentage | Number of eyes |
|---|---|---|
| Visus Oogkliniek | 1.8% | 2.294 ogen |
| Nationaal | 3.1% | 3.086 ogen |
4. Intraocular Lens (IOL) Outcomes – ZEISS AT LISA tri
Visus Oogkliniek – Clinical Outcomes for 2,906 Eyes (2016–2025)
This section presents outcomes based on 2,906 ZEISS AT LISA tri trifocal intraocular lens procedures performed at Visus Oogkliniek between 2016 and 2025. These lenses are used in refractive lens exchange or cataract procedures for patients seeking high-quality vision at distance, intermediate, and near without dependence on glasses.
This section displays our own clinical results for trifocal lens surgery, including:
- Binocular visual acuity at distance, intermediate (≈70–80 cm), and near (≈40 cm)
- Refractive Predictability, including the percentage of eyes within ±0.50 D and ±1.00 D
- Spectacle Independence, based on patient-reported outcomes
- Overall Satisfaction, including the proportion of patients who would choose the same lens again
These data represent real-world Visus patient outcomes and demonstrate the level of visual performance achievable with modern trifocal lens technology when combined with precise diagnostics and surgical planning.
Decimal notation: 1.0 20/20 Snellen
Table 1 — Binocular Uncorrected Visual Acuity (UDVA / UIVA / UNVA)
Distance, intermediate, and near visual acuity results for 2,906 eyes analysed with ZEISS AT LISA tri lenses.
| Time After Surgery | Distance UDVA (far) | Intermediate UIVA (≈70–80 cm) | Near UNVA (≈40 cm) |
|---|---|---|---|
| 1 month | 0.85 | 0.85 | 0.85 |
| 3 months | 0.95 | 0.875 | 0.95 |
| 6–12 months | 0.95 | 0.925 | 0.95 |
Table 2 — Refractive Predictability
Percentage of trifocal IOL cases within ±0.50 D and ±1.00 D of intended postoperative refraction.
| Time After Surgery | % within ±0.50 D of target SE | % within ±1.00 D of target SE | Mean Residual SE (approx.) |
|---|---|---|---|
| 1 month | 88.5% | 97.5% | 0.00 to −0.25 D |
| 3 months | 91% | 98% | 0.00 to −0.25 D |
| 12 months | 92.5% | 98.5% | 0.00 to −0.25 D |
Table 3 — Spectacle Independence & Satisfaction
Patient-reported spectacle independence and satisfaction for Visus trifocal lens recipients.
| Outcome Measure | Visus Result |
|---|---|
| Spectacle independence – distance | 95% |
| Spectacle independence – intermediate | 91.5% |
| Spectacle independence – near | 91.5% |
| Overall satisfaction ("satisfied/very") | 93% |
| Would choose same lens again | 93% |
5. Phakic Lens Outcomes – EVO / EVO+ ICL
Visus Oogkliniek – Clinical Outcomes for 1,002 Eyes (2016–2025)
This section presents outcomes based on 1,002 EVO / EVO+ ICL procedures performed at Visus Oogkliniek between 2016 and 2025. ICL treatment is primarily used for patients with high myopia, thin corneas, irregular corneas, or those who are not suitable candidates for corneal laser treatments. The EVO/EVO+ lens is implanted behind the iris and in front of the natural crystalline lens, allowing refractive correction without altering the corneal structure.
This section presents our own clinical outcomes, including:
- Uncorrected Distance Visual Acuity (UDVA) at early and long-term follow-up
- Refractive Predictability, including the percentage of eyes within ±0.50 D and ±1.00 D of target
- Safety indicators, such as CDVA line changes (gain or loss)
- Long-term stability of visual and refractive outcomes
These results reflect real-world performance of ICL implantation in our clinic and provide patients and clinicians with a transparent overview of the accuracy, safety, and long-term visual quality achieved with this premium lens option.
Table 1 — Uncorrected Distance Visual Acuity (UDVA) Over Time
Postoperative UDVA outcomes for 1,002 ICL eyes analysed at Visus Oogkliniek.
| Time After Surgery | UDVA (decimal, typical) | % of eyes ≥ 20/20 | % of eyes ≥ 20/25 (0.8) |
|---|---|---|---|
| 1 day – 1 week | 0.8 | 55% | 80% |
| 1 month | 0.95 | 90% | 94% |
| 6 months | 1.0 (≈20/20 or better) | 94.5% | 97% |
| 12 months | 1.0 (≈20/20 or better) | 95.5% | 97.5% |
Table 2 — Refractive Predictability
Percentage of ICL-treated eyes within ±0.50 D and ±1.00 D of target refraction.
| Time After Surgery | % within ±0.50 D of target SE | % within ±1.00 D of target SE | Mean Residual SE (approx.) |
|---|---|---|---|
| 1 month | 88.5% | 97.5% | 0.00 to −0.25 D |
| 6 months | 92.5% | 98.5% | 0.00 to −0.25 D |
| 12 months | 93% | 98.5% | 0.00 to −0.25 D |
Table 3 — Safety and CDVA Changes
CDVA line changes and safety metrics for all Visus ICL treatments.
| Parameter | Visus Result |
|---|---|
| Safety index (CDVA postop / CDVA preop) | 1.085 |
| Efficacy index (UDVA postop / CDVA preop) | 1.05 |
| Eyes with CDVA equal or better than preop | 97.5% |
| Eyes gaining ≥1 line of CDVA | 47.5% |
| Eyes losing 1 line of CDVA | 1% |
| Eyes losing ≥2 lines of CDVA | Extremely rare (0.15%) |
Disclaimer & Verantwoording
De gepresenteerde resultaten zijn gebaseerd op interne kwaliteitsmetingen en kunnen variëren afhankelijk van individuele patiëntkenmerken. Resultaten uit het verleden bieden geen garantie voor toekomstige uitkomsten. Alle data wordt regelmatig geaudit en bijgewerkt.
Laatste update: September 2026
Make your free appointment today
To determine whether you are eligible for treatment at Visus Eye Clinic, a comprehensive preliminary examination is performed free of charge and without obligation. This information is essential for determining which treatment is best suited to your eyes, age, and preferences. Because every eye is unique, what is ideal for one person may not be as suitable for another.
- Choose from 6 different locations in the Netherlands
- Plan online at a time that suits you
- Personal treatment advice tailored to your needs